In austerity-stricken Europe, increasing funds are flowing to arms and security firms positioning themselves as experts on border control. Researcher Mark Akkerman documents the companies profiting from E.U. border externalization and the industry’s lobbying power.
The recent report ‘The Netherlands and Synthetic Drugs: An Inconvenient Truth’ argues for increasing resources to expand anti-drug efforts in the Netherlands. In a topical opinion piece, Tom Blickman addresses the crucial issues at hand.
David Bewley-Taylor, Tom Blickman, Martin Jelsma, John Walsh
03 April 2018
Ever since the introduction of Bill C-45, questions have been swirling concerning Canada’s position relative to the UN drug control conventions: conventions to which Canada is a party and that, crucially, prohibit the creation of regulated markets for the recreational use of cannabis.
This brief explores the politics behind the promise of ‘blue growth'. We have discovered that the discourse around blue growth, blue economy, blue revolution and the like is a masterfully mixed and powerful cocktail. The ingredients that make up this mix are the subject of this brief, and our intention is to explore the function of each component of the cocktail.